https://revivethera.com/2020/03/revive-therapeutics-explores-the-use-of-bucillamine-as-a-novel-treatment-for-infectious-diseases-including-covid-19/2020-08-16T13:33:27+00:00https://revivethera.com/2020/02/revive-enters-into-psychedelics-market-with-letter-of-intent-to-acquire-psilocin-pharma-corp/2020-08-16T13:39:23+00:00https://revivethera.com/2020/05/revive-therapeutics-provides-corporate-update-on-its-pharmaceutical-initiatives/2020-05-26T20:49:02+00:00https://revivethera.com/2020/04/revive-therapeutics-provides-an-update-on-its-psilocybin-based-pharmaceutical-program/2020-08-16T13:08:56+00:00https://revivethera.com/2020/04/revive-therapeutics-announces-u-s-fda-recommendation-to-proceed-directly-into-a-phase-3-confirmatory-clinical-trial/2020-08-16T13:12:57+00:00https://revivethera.com/2020/04/revive-therapeutics-announces-research-partnership-agreement-with-the-university-of-wisconsin-madison-to-evaluate-novel-formulations-and-drug-delivery-technology-focused-on-psilocybin-based-pharmaceut/2020-08-16T13:14:40+00:00https://revivethera.com/2020/04/revive-therapeutics-partners-with-complete-phytochemical-solutions-to-advance-research-initiatives-for-psilocybin-based-pharmaceutical-products/2020-08-16T13:16:07+00:00https://revivethera.com/2020/04/revive-therapeutics-announces-closing-of-second-tranche-of-brokered-private-placement/2020-08-16T13:18:37+00:00https://revivethera.com/2020/04/revive-therapeutics-engages-novotech-as-asia-pacific-cro-for-bucillamine-in-the-treatment-of-infectious-diseases/2020-08-16T13:20:24+00:00https://revivethera.com/2020/04/revive-therapeutics-announces-filing-of-fda-pre-ind-meeting/2020-08-16T13:22:09+00:00https://revivethera.com/2020/03/revive-therapeutics-provides-corporate-update-on-its-covid-19-and-infectious-diseases-programs/2020-08-16T13:28:05+00:00https://revivethera.com/2020/03/revive-therapeutics-engages-pharma-olam-and-strengthens-infectious-diseases-clinical-development-team-to-advance-u-s-fda-clinical-study-for-covid-19/2020-08-16T13:29:49+00:00https://revivethera.com/2020/03/revive-therapeutics-appoints-dr-david-boulware-md-as-scientific-advisor-for-infectious-diseases-including-covid-19/2020-08-16T13:31:10+00:00https://revivethera.com/2020/03/revive-therapeutics-announces-closing-of-brokered-private-placement/2020-08-16T13:35:19+00:00https://revivethera.com/2020/03/revive-announces-closing-of-the-acquisition-of-psilocin-pharma-corp/2020-08-16T13:36:41+00:00https://revivethera.com/2020/02/revive-provides-update-on-its-clinical-development-plan-for-cannabidiol-in-the-treatment-of-autoimmune-hepatitis/2020-08-16T13:38:26+00:00https://revivethera.com/2020/02/revive-therapeutics-announces-brokered-private-placement-of-up-to-2-million/2020-08-16T13:40:46+00:00https://revivethera.com/2020/02/revive-therapeutics-to-pursue-the-psychedelic-market-with-agreement-and-investment-in-red-light-holland-financing/2020-08-16T13:42:52+00:00https://revivethera.com/2020/02/revive-therapeutics-announces-offering-of-210000-of-convertible-debenture-units/2020-08-16T13:44:16+00:00https://revivethera.com/2020/01/revive-therapeutics-provides-update-on-its-cannabinoid-program-initiatives-for-drug-delivery-and-in-the-prevention-of-ischemia-and-reperfusion-injury-from-organ-transplantation/2020-08-16T13:45:57+00:00https://revivethera.com/2020/01/revive-therapeutics-provides-update-on-its-clinical-development-plan-for-rare-liver-diseases/2020-08-16T13:48:45+00:00https://revivethera.com/2019/12/revive-therapeutics-provides-update-on-its-cannabis-based-pharmaceutical-initiatives/2020-08-16T13:51:12+00:00https://revivethera.com/2019/12/revive-therapeutics-announces-new-leadership-appointment-and-board-change/2020-08-16T13:53:43+00:00https://revivethera.com/2019/11/revive-therapeutics-announces-results-for-the-three-months-ended-september-30-2019/2020-08-16T13:55:20+00:00https://revivethera.com/2020/06/revive-therapeutics-announces-submission-of-investigational-new-drug-application-ind-with-u-s-fda-for-phase-3-confirmatory-study-for-bucillamine-in-covid-19/2020-06-30T20:22:12+00:00https://revivethera.com/2020/07/revive-therapeutics-announces-u-s-fda-approval-of-confirmatory-phase-3-clinical-trial-for-bucillamine-in-covid-19/2020-08-14T13:57:23+00:00https://revivethera.com/2020/08/revive-therapeutics-advancing-drug-delivery-technology-for-psychedelics-developed-prototypes-of-orally-dissolvable-thin-film-for-psilocybin/2020-08-14T14:04:57+00:00https://revivethera.com/2020/08/revive-therapeutics-signs-mou-with-attwill-medical-solutions-for-phase-3-clinical-trial-for-bucillamine-in-covid-19/2020-08-14T14:07:39+00:00https://revivethera.com/2020/08/revive-therapeutics-signs-mou-with-attwill-medical-solutions-for-phase-3-clinical-trial-for-bucillamine-in-covid-19-2/2020-08-14T14:01:42+00:00https://revivethera.com/2020/06/revive-therapeutics-expands-research-partnership-for-novel-formulation-development-and-clinical-research-of-psilocybin-with-the-university-of-wisconsin-madison/2020-08-14T14:12:26+00:00https://revivethera.com/2020/06/revive-therapeutics-provides-update-on-discussions-with-health-canada-in-pre-cta-meeting/2020-08-14T14:14:39+00:00https://revivethera.com/2020/06/revive-therapeutics-announces-filing-of-a-pre-cta-meeting-request-with-health-canada-and-update-on-u-s-fda-ind-filing-and-phase-3-clinical-trial-design-for-bucillamine-in-the-treatment-of-covid-19/2020-08-14T14:18:17+00:00https://revivethera.com/2020/04/investor-announcement/2020-08-16T13:24:21+00:00https://revivethera.com/2020/09/revive-therapeutics-enters-into-clinical-trial-agreement-to-evaluate-psilocybin-for-the-treatment-of-methamphetamine-use-disorder/2020-09-14T17:26:17+00:00https://revivethera.com/2020/08/revive-therapeutics-announces-irb-approval-for-phase-3-clinical-trial-protocol-for-bucillamine-in-covid-19/2020-09-14T17:27:30+00:00https://revivethera.com/2020/08/revive-therapeutics-announces-submission-of-irb-approval-for-phase-3-clinical-trial-protocol-for-bucillamine-in-covid-19/2020-09-14T17:28:42+00:00https://revivethera.com/2020/08/revive-therapeutics-to-expand-phase-3-clinical-trial-for-bucillamine-in-covid-19-in-asia-pacific-and-canada/2020-09-14T17:30:34+00:00https://revivethera.com/2020/09/revive-therapeutics-announces-irb-approval-of-us-expanded-access-treatment-program-compassionate-use-for-bucillamine-in-covid-19/2020-11-02T16:23:05+00:00https://revivethera.com/2020/09/revive-therapeutics-provides-corporate-update-on-its-psychedelics-therapeutics-programs/2020-11-02T16:21:40+00:00https://revivethera.com/2020/09/revive-therapeutics-announces-update-on-fda-phase-3-clinical-trial-for-bucillamine-in-covid-19/2020-11-02T16:26:04+00:00https://revivethera.com/2020/10/revive-therapeutics-signs-supply-agreement-with-havn-life-sciences-for-psychedelic-compounds/2020-11-02T16:29:48+00:00https://revivethera.com/2020/10/revive-therapeutics-provides-update-on-fda-phase-3-clinical-trial-for-bucillamine-in-covid-19/2020-11-02T16:32:12+00:00https://revivethera.com/2020/11/revive-therapeutics-provides-update-on-oral-thin-film-product-with-psilocybin/2020-11-15T20:52:39+00:00https://revivethera.com/2020/11/revive-therapeutics-announces-research-collaboration-with-pharmather-for-development-of-psilocybin-in-cancer-and-discovery-of-novel-uses-of-psychedelics/2020-11-20T20:09:40+00:00https://revivethera.com/2020/12/epidemiologist-dr-joel-moody-joins-revive-therapeutics-as-medical-and-clinical-advisor/2020-12-02T19:28:16+00:00https://revivethera.com/2020/12/binding-of-sars-cov-2-spike-protein-to-ace2-is-disabled-by-thiol-based-drugs-evidence-from-in-vitro-sars-cov-2-infection-studies/2020-12-14T16:49:07+00:00https://revivethera.com/2020/12/revive-therapeutics-announces-loi-to-acquire-pharmathers-psilocybin-program/2020-12-21T14:14:44+00:00https://revivethera.com/2020/12/revive-therapeutics-provides-update-on-fda-phase-3-clinical-trial-for-bucillamine-in-covid-19-with-plans-on-emergency-use-access/2020-12-23T14:08:10+00:00https://revivethera.com/2020/12/dr-john-fahy-joins-revive-therapeutics-as-scientific-and-clinical-advisor-for-covid-19-fda-phase-3-study/2020-12-31T14:17:18+00:00https://revivethera.com/2021/01/revive-therapeutics-announces-research-collaboration-with-north-carolina-state-university-for-natural-biosynthesis-enzymatic-platform-to-develop-psilocybin/2021-02-09T14:06:25+00:00https://revivethera.com/2021/01/revive-therapeutics-announces-10-million-bought-deal-offering-of-units/2021-02-09T14:06:19+00:00https://revivethera.com/2021/01/revive-therapeutics-announces-upsize-to-previously-announced-bought-deal-offering/2021-02-09T14:06:12+00:00https://revivethera.com/2021/01/revive-therapeutics-included-in-first-psychedelic-exchange-traded-fund/2021-02-09T14:06:07+00:00https://revivethera.com/2021/02/revive-therapeutics-files-business-acquisition-report/2021-02-09T14:06:02+00:00https://revivethera.com/2021/02/revive-therapeutics-receives-receipt-for-final-short-form-prospectus-for-previously-announced-20-million-bought-deal-public-offering/2021-02-10T02:05:52+00:00https://revivethera.com/2021/02/revive-therapeutics-provides-update-on-cannabinoid-pharmaceuticals-program/2021-02-11T14:06:18+00:00https://revivethera.com/2021/02/revive-therapeutics-announces-closing-of-23-0-million-short-form-prospectus-offering/2021-02-12T15:04:56+00:00https://revivethera.com/2021/02/revive-therapeutics-acquires-unique-psilocybin-assets/2021-02-17T14:37:32+00:00https://revivethera.com/2021/02/revive-therapeutics-provides-update-on-fda-phase-3-clinical-trial-for-bucillamine-in-covid-19-with-planned-completion-and-emergency-use-authorization-request/2021-02-26T14:28:56+00:00https://revivethera.com/2021/03/revive-therapeutics-announces-successful-research-results-for-psilocybin-to-treat-traumatic-brain-injury-and-filing-of-international-patent-application/2021-03-19T12:37:38+00:00https://revivethera.com/2021/03/revive-therapeutics-provides-update-on-fda-phase-3-clinical-trial-for-bucillamine-in-covid-19-2/2021-03-24T13:04:10+00:00https://revivethera.com/2021/04/revive-provides-dial-in-information-for-annual-and-special-meeting/2021-04-09T12:59:28+00:00https://revivethera.com/2021/04/revive-reschedules-annual-and-special-meeting-and-provides-dial-in-information/2021-04-16T17:03:34+00:00https://revivethera.com/2021/04/revive-therapeutics-announces-successful-research-results-for-oral-thin-film-psilocybin-and-filing-of-u-s-provisional-patent-application/2021-04-22T13:04:12+00:00https://revivethera.com/2021/04/revive-therapeutics-files-for-fda-orphan-drug-designation-for-psilocybin-in-traumatic-brain-injury/2021-04-27T13:54:18+00:00https://revivethera.com/2021/05/revive-therapeutics-enters-into-research-agreement-with-ucsf-for-bucillamine-as-potential-treatment-for-severe-covid-19/2021-05-03T13:32:44+00:00https://revivethera.com/2021/05/revive-therapeutics-enters-into-feasibility-agreement-with-lts-lohmann-to-develop-oral-psilocybin-thin-film-strip/2021-05-17T13:59:05+00:00https://revivethera.com/2021/06/revive-therapeutics-partners-with-supriya-to-pursue-eua-for-bucillamine-to-treat-covid-in-india/2021-06-08T13:03:57+00:00https://revivethera.com/2021/06/revive-to-present-at-the-h-c-wainwright-psychedelics-in-psychiatry-and-beyond-virtual-conference/2021-06-14T21:14:36+00:00https://revivethera.com/2021/06/revive-collaborates-with-university-of-health-sciences-antigua-to-pioneer-clinical-research-of-psychedelics/2021-06-17T12:44:38+00:00https://revivethera.com/2021/06/revive-therapeutics-approved-to-trade-on-the-otcqb-market/2021-06-25T20:20:24+00:00https://revivethera.com/2021/07/revive-therapeutics-provides-update-on-fda-phase-3-clinical-trial-for-bucillamine-in-covid-19-3/2021-07-15T18:08:48+00:00https://revivethera.com/2021/08/revive-therapeutics-provides-update-on-psychedelics-clinical-product-pipeline/2021-08-11T12:19:39+00:00https://revivethera.com/2021/08/revive-confirms-no-material-undisclosed-information/2021-08-12T14:11:35+00:00https://revivethera.com/2021/08/revive-therapeutics-signs-exclusive-worldwide-license-agreement-for-medicinal-mushroom-ganoderma-lucidum-to-treat-cancer/2021-08-17T22:04:02+00:00https://revivethera.com/2021/09/revive-therapeutics-included-in-advisorshares-newly-launched-psychedelics-etf/2021-09-21T14:14:48+00:00https://revivethera.com/2021/10/revive-therapeutics-provides-update-on-fda-phase-3-clinical-trial-for-bucillamine-in-covid-19-4/2021-10-26T12:27:05+00:00https://revivethera.com/2021/11/revive-therapeutics-enters-into-research-collaboration-agreement-with-pharmather-for-development-of-psilocybin-microneedle-patch/2021-11-03T12:48:20+00:00https://revivethera.com/2021/11/revive-therapeutics-announces-published-research-results-on-bucillamine-as-potential-inhibitor-of-sars-cov-2-infection-delta-variant/2021-12-07T20:40:05+00:00https://revivethera.com/2021/11/revive-therapeutics-files-for-fda-orphan-drug-designation-for-bucillamine-in-the-prevention-of-ischemia-reperfusion-injury-during-liver-transplantation/2021-12-07T20:37:29+00:00https://revivethera.com/2021/12/revive-therapeutics-expands-bucillamine-research-to-treat-omicron-variant-and-adds-inflammatory-markers-to-fda-phase-3-clinical-trial/2021-12-07T20:35:19+00:00https://revivethera.com/2021/12/revive-therapeutics-provides-update-on-phase-3-clinical-trial-for-bucillamine-in-covid-19/2021-12-29T22:01:42+00:00https://revivethera.com/2022/01/revive-therapeutics-clarifies-status-of-its-phase-3-clinical-trial-for-bucillamine-in-covid-19/2022-01-19T03:06:02+00:00https://revivethera.com/2022/01/revive-therapeutics-provides-update-of-psilocybin-pharmaceutical-programs/2022-01-19T03:06:12+00:00https://revivethera.com/2022/01/revive-therapeutics-provides-update-on-phase-3-clinical-trial-for-bucillamine-in-covid-19-2/2022-01-19T03:16:37+00:00https://revivethera.com/2022/02/revive-therapeutics-provides-update-on-phase-3-clinical-trial-for-bucillamine-in-covid-19-3/2022-02-14T13:06:04+00:00https://revivethera.com/2022/02/revive-therapeutics-receives-fda-orphan-drug-designation-for-bucillamine-in-the-prevention-of-ischemia-reperfusion-injury-during-liver-transplantation/2022-02-15T21:56:47+00:00https://revivethera.com/2022/02/havn-life-secures-purchase-order-for-controlled-substance-sale-to-revive-therapeutics-ltd-for-use-in-clinical-research/2022-02-24T14:24:13+00:00https://revivethera.com/2022/03/revive-therapeutics-provides-update-on-phase-3-clinical-trial-for-bucillamine-in-covid-19-4/2022-03-29T13:11:26+00:00https://revivethera.com/2022/04/revive-therapeutics-provides-update-on-phase-3-clinical-trial-for-bucillamine-in-covid-19-5/2022-04-11T23:13:32+00:00https://revivethera.com/2022/04/revive-therapeutics-announces-publication-of-research-data-with-bucillamine-in-covid-19/2022-04-18T15:20:25+00:00https://revivethera.com/2022/04/revive-therapeutics-provides-update-on-phase-3-clinical-trial-for-bucillamine-in-covid-19-6/2022-04-25T21:32:25+00:00https://revivethera.com/2022/05/revive-therapeutics-provides-update-on-phase-3-clinical-trial-for-bucillamine-in-covid-19-7/2022-05-16T20:11:07+00:00https://revivethera.com/2022/05/revive-therapeutics-provides-update-on-phase-3-clinical-trial-for-bucillamine-in-covid-19-8/2022-05-26T14:56:16+00:00https://revivethera.com/2022/05/revive-therapeutics-advances-inflammatory-liver-disorders-programs-for-autoimmune-hepatitis-and-liver-transplantation/2022-05-31T12:38:11+00:00https://revivethera.com/2022/06/revive-therapeutics-provides-update-on-phase-3-clinical-trial-for-bucillamine-in-covid-19-9/2022-06-06T18:35:06+00:00https://revivethera.com/2022/06/revive-therapeutics-provides-update-on-phase-3-clinical-trial-for-bucillamine-in-covid-19-10/2022-06-24T15:50:13+00:00https://revivethera.com/2022/07/revive-therapeutics-provides-update-on-phase-3-clinical-trial-for-bucillamine-in-covid-19-11/2022-07-25T16:22:21+00:00https://revivethera.com/2022/08/revive-therapeutics-provides-update-on-phase-3-clinical-trial-for-bucillamine-in-covid-19-12/2022-08-16T12:18:11+00:00https://revivethera.com/2022/08/notice-of-annual-and-special-meeting-of-shareholders/2022-08-19T19:52:34+00:00https://revivethera.com/2022/09/revive-therapeutics-announces-submission-of-amended-phase-3-covid-19-study-protocol-to-fda/2022-09-14T11:53:13+00:00https://revivethera.com/2022/09/revive-therapeutics-provides-update-on-the-psilocybin-clinical-study-for-methamphetamine-use-disorder-and-oral-psilocybin-thin-film-strip-program/2022-09-16T12:31:30+00:00https://revivethera.com/2022/09/revive-therapeutics-provides-update-on-phase-3-clinical-trial-for-bucillamine-in-covid-19-13/2022-09-28T11:56:49+00:00https://revivethera.com/2022/10/revive-therapeutics-provides-update-on-phase-3-clinical-trial-for-bucillamine-in-covid-19-14/2022-10-06T15:35:47+00:00https://revivethera.com/2022/10/revive-therapeutics-announces-finalization-of-amended-phase-3-covid-19-study-protocol-to-fda/2022-10-14T17:50:04+00:00https://revivethera.com/2022/11/revive-therapeutics-announces-fda-recommendation-for-type-c-meeting-to-discuss-amended-protocol-agreement-of-phase-3-clinical-study-for-bucillamine-in-the-treatment-of-covid-19/2022-11-22T14:50:21+00:00https://revivethera.com/2022/11/revive-therapeutics-announces-update-for-type-c-meeting-to-discuss-amended-protocol-agreement-of-phase-3-clinical-study-for-bucillamine-in-the-treatment-of-covid-19/2022-11-24T15:02:21+00:00https://revivethera.com/2022/11/revive-therapeutics-ltd-announces-offering-of-up-to-5-million/2022-12-01T00:22:09+00:00https://revivethera.com/2022/12/revive-therapeutics-ltd-expands-life-offering-to-quebec/2022-12-15T12:41:38+00:00https://revivethera.com/2022/12/revive-therapeutics-announces-submission-of-type-c-meeting-request-to-fda-for-amended-protocol-agreement-of-phase-3-clinical-study-for-bucillamine-in-the-treatment-of-covid-19/2022-12-23T00:57:38+00:00https://revivethera.com/2023/01/revive-therapeutics-announces-type-c-meeting-request-granted-by-fda-for-amended-protocol-agreement-of-phase-3-clinical-study-for-bucillamine-in-the-treatment-of-covid-19/2023-01-05T16:04:28+00:00https://revivethera.com/2023/01/revive-therapeutics-announces-publication-showing-bucillamines-potential-impact-on-covid-19-omicron-variants/2023-01-09T20:43:02+00:00https://revivethera.com/2023/01/revive-therapeutics-ltd-closes-4-3-million-offering/2023-01-12T19:29:51+00:00https://revivethera.com/2023/01/revive-therapeutics-to-submit-updated-briefing-package-in-support-of-upcoming-type-c-meeting-granted-by-fda-for-amended-protocol-agreement-of-phase-3-clinical-study-for-bucillamine-in-the-treatment-of/2023-01-12T19:31:53+00:00https://revivethera.com/2023/01/revive-therapeutics-submits-updated-briefing-package-in-support-of-upcoming-type-c-meeting-granted-by-fda-for-amended-protocol-agreement-of-phase-3-clinical-study-for-bucillamine-in-the-treatment-of-c/2023-01-19T22:41:46+00:00https://revivethera.com/2023/02/revive-therapeutics-enters-into-research-collaboration-agreement-with-pharmather-for-development-of-mdma-transdermal-patch/2023-02-03T13:40:14+00:00https://revivethera.com/2023/02/revive-therapeutics-secures-mdma-supply-from-pharmala-biotech-for-mdma-transdermal-patch-development/2023-02-06T14:42:09+00:00https://revivethera.com/2023/03/revive-therapeutics-provides-update-from-type-c-meeting-with-fda-for-amended-protocol-agreement-of-phase-3-clinical-study-for-bucillamine-in-the-treatment-of-covid-19/2023-03-08T13:13:23+00:00https://revivethera.com/2023/03/revive-therapeutics-provides-update-of-phase-3-clinical-study-for-bucillamine-in-the-treatment-of-covid-19/2023-03-20T14:50:37+00:00https://revivethera.com/2023/03/revive-therapeutics-provides-update-on-psilocybin-clinical-study-for-methamphetamine-use-disorder/2023-03-28T11:44:04+00:00https://revivethera.com/2023/04/revive-therapeutics-advances-mdma-transdermal-patch-development-with-purchase-of-mdma-supply-from-pharmala-biotech/2023-04-03T11:53:40+00:00https://revivethera.com/2023/04/revive-therapeutics-provides-update-of-phase-3-clinical-study-for-bucillamine-in-the-treatment-of-covid-19-2/2023-04-19T01:41:01+00:00https://revivethera.com/2023/05/revive-therapeutics-announces-data-safety-monitoring-board-meeting-date-on-phase-3-clinical-study-of-bucillamine-in-the-treatment-of-covid-19/2023-05-02T13:16:05+00:00https://revivethera.com/2023/05/revive-therapeutics-provides-update-of-phase-3-clinical-study-for-bucillamine-in-the-treatment-of-covid-19-3/2023-05-12T11:37:03+00:00https://revivethera.com/2023/05/revive-therapeutics-provides-update-of-phase-3-clinical-study-for-bucillamine-in-the-treatment-of-covid-19-4/2023-05-30T11:58:30+00:00https://revivethera.com/2023/07/revive-therapeutics-announces-results-of-phase-3-clinical-study-for-bucillamine-in-the-treatment-of-covid-19/2023-07-06T13:21:28+00:00https://revivethera.com/2023/07/revive-therapeutics-announces-filing-of-patent-for-bucillamine-in-the-treatment-of-exposure-to-chemical-warfare-agents/2023-07-28T12:36:52+00:00https://revivethera.com/2023/08/revive-therapeutics-announces-initiation-of-novel-bucillamine-formulation-development/2023-08-22T14:17:12+00:00https://revivethera.com/2023/10/revive-therapeutics-provides-update-of-novel-bucillamine-formulation-development/2023-10-11T15:42:08+00:00https://revivethera.com/2023/10/revive-therapeutics-enters-into-agreement-with-defence-research-and-development-canada-for-evaluating-bucillamine-for-nerve-agent-exposure/2023-10-17T13:19:54+00:00https://revivethera.com/2023/11/revive-therapeutics-enters-into-worldwide-exclusive-agreement-with-lawson-health-research-institute-to-develop-and-commercialize-a-novel-long-covid-rapid-test/2023-11-06T13:49:57+00:00https://revivethera.com/2023/11/revive-therapeutics-provides-update-of-novel-bucillamine-formulation-development-2/2023-11-21T13:14:09+00:00https://revivethera.com/2023/12/revive-therapeutics-collaborates-with-attwill-medical-solutions-for-the-clinical-and-commercial-development-of-a-novel-lyophilized-formulation-of-bucillamine/2023-12-18T13:52:30+00:00https://revivethera.com/2023/12/revive-therapeutics-announces-results-of-annual-general-and-special-meeting-of-shareholders/2023-12-20T17:58:07+00:00https://revivethera.com/2024/01/revive-therapeutics-successfully-completes-development-of-a-novel-lyophilized-formulation-of-bucillamine/2024-01-10T13:09:15+00:00https://revivethera.com/2024/01/revive-therapeutics-provides-update-evaluating-bucillamine-for-nerve-agent-exposure-with-defence-research-and-development-canada/2024-01-16T13:21:20+00:00https://revivethera.com/2024/01/revive-therapeutics-ltd-announces-offering-of-up-to-3-million/2024-01-25T14:18:49+00:00https://revivethera.com/2024/01/revive-therapeutics-ltd-announces-closing-of-the-first-tranche-of-its-private-placement-for-gross-proceeds-of-913500/2024-01-31T23:34:31+00:00https://revivethera.com/2024/02/revive-therapeutics-explores-the-use-of-bucillamine-for-long-covid/2024-02-01T13:56:36+00:00https://revivethera.com/2024/02/revive-therapeutics-ltd-announces-closing-of-the-second-and-final-tranche-of-its-private-placement-for-gross-proceeds-of-1187110/2024-02-26T21:54:49+00:00https://revivethera.com/2024/03/revive-therapeutics-provides-corporate-update/2024-03-12T13:18:34+00:00https://revivethera.com/2024/03/revive-therapeutics-to-submit-type-c-meeting-request-with-fda-for-bucillamine-to-treat-long-covid/2024-03-19T12:16:51+00:00https://revivethera.com/2024/03/revive-therapeutics-submits-type-c-meeting-request-package-to-fda-for-clinical-study-of-bucillamine-to-treat-long-covid/2024-03-27T14:02:57+00:00https://revivethera.com/2024/04/revive-therapeutics-provides-update-on-psilocybin-clinical-study-for-methamphetamine-use-disorder-2/2024-04-02T12:34:55+00:00https://revivethera.com/2024/04/revive-therapeutics-announces-fda-acceptance-of-meeting-request-for-long-covid-diagnostic-product/2024-04-18T12:56:33+00:00https://revivethera.com/2024/04/revive-therapeutics-announces-type-c-meeting-request-granted-by-fda-for-clinical-study-of-bucillamine-to-treat-long-covid/2024-04-23T12:31:54+00:00https://revivethera.com/2024/06/revive-therapeutics-provides-update-from-fda-meeting-for-long-covid-diagnostic-product/2024-06-10T12:28:34+00:00https://revivethera.com/2024/06/revive-therapeutics-provides-update-on-fda-type-c-meeting-for-clinical-study-of-bucillamine-to-treat-long-covid/2024-06-12T13:35:44+00:00https://revivethera.com/2024/07/revive-therapeutics-provides-update-on-research-study-evaluating-bucillamine-for-nerve-agent-exposure/2024-07-02T21:10:51+00:00https://revivethera.com/2024/08/revive-therapeutics-provides-update-on-research-study-evaluating-bucillamine-for-nerve-agent-exposure-and-expansion-into-viral-infections/2024-08-28T13:02:11+00:00https://revivethera.com/2024/09/revive-therapeutics-announces-strategic-focus-on-bucillamine-for-infectious-diseases-and-medical-countermeasures/2024-09-18T12:49:28+00:00https://revivethera.com/2024/10/revive-therapeutics-provides-update-on-research-study-evaluating-bucillamine-for-nerve-agent-exposure-2/2024-10-31T12:07:14+00:00https://revivethera.com/2024/11/revive-therapeutics-announces-publication-demonstrating-novel-therapeutic-approach-of-psilocybin-in-stroke/2024-11-12T13:14:32+00:00https://revivethera.com/2025/01/revive-therapeutics-provides-update-on-research-study-evaluating-bucillamine-for-nerve-agent-exposure-3/2025-01-08T13:14:56+00:00https://revivethera.com/2025/02/revive-therapeutics-announces-update-on-rd-focus-on-bucillamine-for-infectious-diseases-and-medical-countermeasures/2025-02-03T23:58:03+00:00https://revivethera.com/2025/03/revive-therapeutics-announces-loi-to-acquire-diagnameds-molecular-hydrogen-program/2025-03-03T15:20:50+00:00https://revivethera.com/2025/03/revive-therapeutics-announces-results-of-annual-shareholder-meeting/2025-03-19T13:59:00+00:00https://revivethera.com/2025/04/revive-therapeutics-announces-acquisition-of-molecular-hydrogen-program/2025-04-01T12:13:51+00:00https://revivethera.com/2025/04/revive-therapeutics-to-investigate-bucillamines-potential-in-cancer-treatment/2025-04-10T12:02:01+00:00https://revivethera.com/2025/04/revive-therapeutics-announces-proposed-shares-for-debt-transaction/2025-04-21T20:56:18+00:00https://revivethera.com/2025/05/revive-therapeutics-provides-update-on-research-study-evaluating-bucillamine-for-nerve-agent-exposure-4/2025-05-12T18:16:16+00:00https://revivethera.com/2025/06/revive-therapeutics-advances-with-next-generation-bucillamine-development/2025-06-04T11:56:47+00:00https://revivethera.com/2025/06/revive-therapeutics-nears-completion-of-key-nerve-agent-countermeasure-study-with-canadian-department-of-national-defence-highlighting-significant-stockpiling-opportunity/2025-06-26T11:54:41+00:00https://revivethera.com/2025/07/revive-therapeutics-clarifies-completion-of-key-nerve-agent-countermeasure-study/2025-07-09T00:52:38+00:00https://revivethera.com/2025/07/revive-therapeutics-announces-proposed-private-placement-and-debt-settlement/2025-07-31T12:22:48+00:00https://revivethera.com/2025/08/revive-therapeutics-announces-closing-of-first-tranche-of-private-placement-and-debt-settlement/2025-08-12T01:48:32+00:00https://revivethera.com/2025/09/revive-therapeutics-announces-extension-of-proposed-private-placement/2025-09-06T18:55:31+00:00https://revivethera.com/2025/09/revive-therapeutics-announces-closing-of-second-tranche-of-private-placement/2025-09-20T20:34:33+00:00https://revivethera.com/2025/11/revive-therapeutics-provides-update-of-key-nerve-agent-countermeasure-study/2025-11-21T17:40:56+00:00https://revivethera.com/2025/12/revive-therapeutics-provides-update-of-key-nerve-agent-countermeasure-study-2/2025-12-15T14:06:59+00:00https://revivethera.com/2026/03/revive-therapeutics-strengthens-bucillamine-ip-portfolio-with-north-american-patent-filings-for-nerve-agent-exposure-and-granted-canadian-patent-for-infectious-diseases/2026-03-11T13:19:49+00:00